Connect your AI

Anika Therapeutics ANIK Deferred Taxes

Deferred Taxes at other companies

StrykerSYK

-$33M-336%

Zimmer Biomet HoldingsZBH

-$21.8M-82.8%

Pacira BioSciences, Inc.PCRX

$1.73M+23.8%

BioventusBVS

$135K+214%

Globus MedicalGMED

$7.96M+1,464%

Organogenesis Holdings Inc.ORGO

-$15.37M-1,114%

Other financials

Income statement

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxExpenseBenefit.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's deferred taxes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's deferred taxes?: Anika Therapeutics (ANIK) reported deferred taxes of $108K in Q1 2026.
How has Anika Therapeutics's deferred taxes changed year-over-year?: Anika Therapeutics's deferred taxes increased by 500.0% year-over-year, from $18K to $108K.
What is the long-term trend for Anika Therapeutics's deferred taxes?: Over 3 years (2021 to 2025), Anika Therapeutics's deferred taxes has grown at a -84.2% compound annual growth rate (CAGR), from -$1.77M to -$7K.
What does deferred taxes mean?: Non-cash deferred tax expense or benefit representing the change in deferred tax assets/liabilities during the period.